Markets Stocks

5.49 +0.34 +6.60%
05:20:00 PM EDT 6/13/2025 NASO


23andMe Stock Snapshot

151.20 M
Market Cap in USD
20.50 M
Number of Shares
27.54 M
Total Number of Shares
0.00
Dividend in USD
0.00
Dividend Yield
52.17
Free Float in %
-10.88
EPS in USD
-0.97
Book Value per Share in USD
-6.57
Cash Flow per Share in USD

23andMe Analyst Opinions

Date Analyst Rating Price

23andMe Estimates* in USD

  2026 2027
Revenue - -
Dividend - -
Dividend Yield (in %) 0.00 % 0.00 %
EPS - -
P/E Ratio -0.55 -0.75
EBIT - -
EBITDA - -
Net Profit - -
Net Profit Adjusted - -
Pre-Tax Profit - -
Pre-Tax Profit Reported - -
EPS (Non-GAAP) ex. SOE - -
EPS (GAAP) - -
Gross Income - -
Cash Flow from Investing - -
Cash Flow from Operations - -
Cash Flow from Financing - -
Cash Flow per Share - -
Free Cash Flow - -
Free Cash Flow per Share - -
Book Value per Share - -
Net Debt - -
Research & Development Exp. - -
Capital Expenditure - -
Selling, General & Admin. Exp. - -
Shareholder’s Equity - -
Total Assets - -

Income Statements in Mio. USD

2025 2024 2023 2022 2021 2020 2019
Sales 189.90 219.64 299.49 271.89 243.92 305.46 440.90
Change of sales in % -13.54 -26.66 10.15 11.47 -20.15 -30.72 -
Gross profit on sales 76.65 69.90 98.00 106.80 96.76 115.18 182.99
Gross profit on sales change in % 9.67 -28.68 -8.24 10.37 -15.99 -37.05 -
Operating income -179.20 -318.98 -324.01 -244.75 -185.20 -213.76 -188.78
Operating income change in % 43.82 1.55 -32.38 -32.16 13.36 -13.23 -
Income before tax -235.24 -666.63 -314.43 -220.97 -183.62 -250.86 -183.53
Income before tax change in % 64.71 -112.01 -42.29 -20.34 26.81 -36.69 -
Income after tax -235.20 -666.70 -311.66 -217.49 -183.62 -250.86 -183.53
Income after tax change in % 64.72 -113.92 -43.30 -18.45 26.81 -36.69 -

Balance Sheet in Mio. USD

2025 2024 2023 2022 2021 2020 2019
Total liabilities 186.64 206.65 228.66 236.41 210.37 270.43 -
Long-term liabilities per share 0.02 3.24 - - 4.37 6.45 -
Equity -26.74 188.52 713.94 915.66 241.73 134.20 -
Equity change in % -114.19 -73.59 -22.03 - 4.07 - -
Balance sheet total 159.89 395.17 942.60 1,152.07 452.10 404.63 -
Balance sheet total change in % -59.54 -58.08 -18.18 154.83 11.73 - -

Key Data in USD

2025 2024 2023 2022 2021 2020 2019
Sales per share 7.36 9.23 0.66 0.75 12.00 15.03 21.70
P/E ratio (year end quote, basic EPS) - - - - - - -
P/E ratio (year end quote, diluted EPS) - - - - - - -
Dividend yield in % 0.00 0.00 0.00 0.00 0.00 - -
Equity ratio in % -16.72 47.71 75.74 79.48 53.47 33.17 -
Debt ratio in % 116.72 52.29 24.26 20.52 46.53 66.83 -

23andMe Insider Activity

Name Date shares traded shares held Price type (sell/buy) option
Selsavage Joseph Anthony 05/19/2025 5,073.00 91,395.00 3.36 Sell No
Selsavage Joseph Anthony 02/19/2025 5,654.00 96,468.00 2.74 Sell No
Selsavage Joseph Anthony 11/19/2024 5,279.00 102,122.00 3.15 Sell No
MONTGOMERY RICE VALERIE MD 08/25/2024 658,485.00 1,013,366.00 n/a Buy No
MONTGOMERY RICE VALERIE MD 08/25/2024 194,552.00 1,207,918.00 0.33 Buy No
Hernandez Sandra R MD 08/25/2024 149,655.00 1,203,204.00 0.33 Buy No
Hernandez Sandra R MD 08/25/2024 658,485.00 1,053,549.00 n/a Buy No
Taylor Peter J. 08/25/2024 658,485.00 981,217.00 n/a Buy No
Richards William G 08/19/2024 57,365.00 573,069.00 0.36 Sell No
HIBBS KATHY L 05/19/2024 35,282.00 1,217,033.00 0.55 Sell No
Selsavage Joseph Anthony 05/19/2024 36,913.00 1,258,390.00 0.55 Sell No
HIBBS KATHY L 05/01/2024 38,551.00 1,252,315.00 0.49 Sell No
HIBBS KATHY L 05/01/2024 38,551.00 1,290,866.00 0.42 Buy No
HIBBS KATHY L 04/17/2024 38,548.00 1,252,315.00 0.47 Sell No
HIBBS KATHY L 04/17/2024 38,548.00 1,290,863.00 0.42 Buy No
HIBBS KATHY L 04/03/2024 38,548.00 1,252,315.00 0.50 Sell No
HIBBS KATHY L 04/03/2024 38,548.00 1,290,863.00 0.42 Buy No
HIBBS KATHY L 03/20/2024 38,548.00 1,252,315.00 0.46 Sell No
HIBBS KATHY L 03/20/2024 38,548.00 1,290,863.00 0.42 Buy No
HIBBS KATHY L 03/06/2024 38,548.00 1,252,315.00 0.53 Sell No
HIBBS KATHY L 03/06/2024 38,548.00 1,290,863.00 0.42 Buy No
HIBBS KATHY L 02/21/2024 38,548.00 1,239,827.00 0.61 Sell No
HIBBS KATHY L 02/21/2024 38,548.00 1,278,375.00 0.42 Buy No
Richards William G 02/19/2024 18,497.00 646,540.00 0.72 Sell No
HIBBS KATHY L 02/14/2024 38,548.00 1,280,349.00 0.78 Sell No

23andMe Dividend Calendar

Date Name Dividend *yield Currency
2025 23andMe Holding Co Registered Shs 0.00 0.00 USD
2024 23andMe Holding Co Registered Shs 0.00 0.00 USD
2023 23andMe Holding Co Registered Shs 0.00 0.00 USD
2022 23andMe Holding Co Registered Shs 0.00 0.00 USD
2021 23andMe Holding Co Registered Shs 0.00 0.00 USD
2020 23andMe Holding Co Registered Shs 0.00 - USD
2019 23andMe Holding Co Registered Shs - - USD
*Yield of the Respective Date

23andMe Calendar

Event Estimate Info Date
Earnings Report - Q1 2026 Earnings Release 08/06/2025
Earnings Report - Q2 2026 Earnings Release 11/05/2025
Earnings Report - Q3 2026 Earnings Release 02/11/2026

23andMe Past Events

Event Actual EPS Info Date
Earnings Report -3.621 USD Q4 2025 Earnings Release 05/22/2025
Earnings Report -2.010 USD Q3 2025 Earnings Release 01/28/2025
Earnings Report -2.320 USD Q2 2025 Earnings Release 11/12/2024
Annual General Meeting -28.000 USD Annual General Meeting 08/26/2024
Earnings Report -2.800 USD Q1 2025 Earnings Release 08/08/2024
Earnings Report -8.600 USD Q4 2024 Earnings Release 05/23/2024
Earnings Report -11.600 USD Q3 2024 Earnings Release 02/07/2024
Earnings Report -3.200 USD Q2 2024 Earnings Release 11/08/2023
Annual General Meeting -0.690 USD Annual General Meeting 09/06/2023
Earnings Report -4.600 USD Q1 2024 Earnings Release 08/08/2023
Earnings Report -0.140 USD Q4 2023 Earnings Release 05/25/2023
Earnings Report -4.000 USD Q3 2023 Earnings Release 02/08/2023
Earnings Report -3.000 USD Q2 2023 Earnings Release 11/07/2022
Annual General Meeting -0.600 USD Annual General Meeting 08/25/2022
Earnings Report -4.000 USD Q1 2023 Earnings Release 08/08/2022
Earnings Report -0.160 USD Q4 2022 Earnings Release 05/26/2022
Earnings Report -4.200 USD Q3 2022 Earnings Release 02/10/2022

23andMe Profile

23andMe Holding Co. is a consumer genetics and research company, which engages in assisting people to access, understand, and benefit from the human genome. It operates through the Consumer and Research Services, and Therapeutics segments. The Consumer and Research Services segment consists of Personal Genome Service, Telehealth Business, and Research Services. The Therapeutics segment focuses on the genetic insights of genetic and phenotypic information. The company was founded by Anne E. Wojcicki in 2006 and is headquartered in San Francisco, CA. .
OSZAR »